Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

15.0%

3 terminated out of 20 trials

Success Rate

78.6%

-7.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 11 completed with results

Key Signals

79% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (6)
P 1 (9)
P 2 (1)

Trial Status

Completed11
Recruiting3
Terminated3
Unknown2
Withdrawn1

Trial Success Rate

78.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT05359848Not ApplicableRecruitingPrimary

A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy

NCT05356182Not ApplicableRecruitingPrimary

A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies

NCT05385718CompletedPrimary

Ezra Faster Scan Study

NCT06097533Phase 2RecruitingPrimary

Improvement of Quality of Life by Cannabinoids in Oncologic Patients

NCT05423808Not ApplicableWithdrawn

Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients.

NCT01409135Phase 1Completed

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

NCT04931329UnknownPrimary

Onco-haematology Vigilance Card

NCT02427490Not ApplicableCompleted

A Problem-Solving Intervention for Family Caregivers in Palliative Oncology

NCT02253420Phase 1CompletedPrimary

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

NCT02824042Phase 1CompletedPrimary

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

NCT02366949Phase 1CompletedPrimary

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

NCT02639091Phase 1CompletedPrimary

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

NCT02138812Phase 1TerminatedPrimary

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

NCT02439346Phase 1TerminatedPrimary

Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

NCT02368951Phase 1TerminatedPrimary

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

NCT02645357Not ApplicableCompletedPrimary

Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients

NCT02906423CompletedPrimary

Results From a Health System-wide Implementation of a Quality of Life Questionnaire

NCT02357953CompletedPrimary

Transpulmonary Thermodilution Using an Implented Central Venous Access Port

NCT02457351Phase 1CompletedPrimary

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

NCT02327806Not ApplicableUnknownPrimary

The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance

Showing all 20 trials

Research Network

Activity Timeline